generic drugs

Drugs to treat multiple sclerosis can run $70,000 a year or more. Patients hoped competition from a generic version of one of the most popular brands would spur relief, but prices went up. Here's why.

The snakebite antivenin CroFab, on the U.S. market since 2000, now faces competition from a drug called Anavip. But both are expensive. "Perverse incentives" keep prices high, says one legal scholar.

A new book investigates the history of unsafe and deceptive practices by some generic drug manufacturers, and explains why U.S. regulators struggle to keep up with a global industry.

Biologic drugs, often made with the help of living organisms, are especially lucrative because they have scant competition from biosimilars, drugs akin to generics. It's a different story in Europe.

A consortium of hospital systems and three foundations is moving ahead with a nonprofit drugmaker that would produce some of the generic medicines health care facilities need the most.